Suchen
Abivax SA
ABVXZur Watchlist hinzufügen
87.580USD
-2.620-2.90%
Handelsschluss 11-13 16:00（ET）
7.64BMarktkapitalisierung
0.00KGV TTM
Über Abivax SA Unternehmen
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA Profil
BörsenkürzelABVX
Name des UnternehmensAbivax SA
IPO-datumJun 26, 2015
CEOde Garidel (Marc)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
Geschäftsjahresende- -
Addresse7-11 Boulevard Haussmann
StadtPARIS
BörseNASDAQ OMX - NASDAQ BASIC
LandFrance
Postleitzahl75009
Telefon33153830963
Websitehttps://www.abivax.com/
BörsenkürzelABVX
IPO-datumJun 26, 2015
CEOde Garidel (Marc)
Führungskräfte von Abivax SA
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kevin Shan, Ph.D.
Mr. Kevin Shan, Ph.D.
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Dr. Dominik Hoechli, M.D.
Dr. Dominik Hoechli, M.D.
Independent Director
Independent Director
--
--
Ms. Nadege Briancon-Eris, Ph.D.
Ms. Nadege Briancon-Eris, Ph.D.
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Ms. Mary Mantock
Ms. Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Ms. Hema Keshava
Ms. Hema Keshava
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Douglas Jacobstein, M.D.
Dr. Douglas Jacobstein, M.D.
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Ms. Jennifer Fine
Ms. Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Mr. Kim Kelly
Mr. Kim Kelly
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Keith Fournier, Ph.D.
Dr. Keith Fournier, Ph.D.
Senior Vice President - Global Regulatory Affair
Senior Vice President - Global Regulatory Affair
--
--
Dr. Maurus de la Rosa, Ph.D.
Dr. Maurus de la Rosa, Ph.D.
Senior Vice President - Research
Senior Vice President - Research
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kevin Shan, Ph.D.
Mr. Kevin Shan, Ph.D.
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Dr. Dominik Hoechli, M.D.
Dr. Dominik Hoechli, M.D.
Independent Director
Independent Director
--
--
Ms. Nadege Briancon-Eris, Ph.D.
Ms. Nadege Briancon-Eris, Ph.D.
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Ms. Mary Mantock
Ms. Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Ms. Hema Keshava
Ms. Hema Keshava
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Douglas Jacobstein, M.D.
Dr. Douglas Jacobstein, M.D.
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Abivax SA?
Die fünf größten Anteilseigner von Abivax SA sind: Mr. Pierre Courteille
Wie viele Institutionen halten Anteile an Abivax SA (ABVX)?
Mit Stand vom 2026Q1 halten 353 Institutionen Anteile an Abivax SA, mit einem Gesamtmarktwert von etwa 61.40M, was 78.18% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -289711.00 gestiegen.